AstraZeneca (AZN) Given a GBX 5,800 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. set a GBX 5,800 ($77.22) price objective on AstraZeneca (LON:AZN) in a report issued on Monday, May 28th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Other equities research analysts have also issued reports about the company. Berenberg Bank raised their price objective on AstraZeneca from GBX 5,800 ($77.22) to GBX 6,000 ($79.88) and gave the stock a buy rating in a research note on Thursday, February 8th. BNP Paribas restated an outperform rating and set a GBX 5,600 ($74.56) target price on shares of AstraZeneca in a report on Thursday, March 22nd. Kepler Capital Markets restated a buy rating and set a GBX 5,250 ($69.90) target price on shares of AstraZeneca in a report on Tuesday, January 30th. Barclays reiterated a top pick rating and issued a GBX 6,300 ($83.88) price objective on shares of AstraZeneca in a research note on Monday, February 5th. Finally, Credit Suisse Group reiterated an outperform rating and issued a GBX 5,800 ($77.22) price objective on shares of AstraZeneca in a research note on Tuesday, February 20th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of GBX 5,321.39 ($70.85).
AZN traded up GBX 89 ($1.18) during trading hours on Monday, hitting GBX 5,448 ($72.53). The company’s stock had a trading volume of 2,055,169 shares, compared to its average volume of 2,310,000. AstraZeneca has a fifty-two week low of GBX 4,260 ($56.72) and a fifty-two week high of GBX 5,520 ($73.49).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.